Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 1/20 | 1.00 |
| ▸ | MAOA | P21397 | 7/20 | 0.85 |
| ▸ | MAOB | P27338 | 7/20 | 0.85 |
| ▸ | MAPT | P10636 | 4/20 | 0.85 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.85 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.85 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.85 |
| ▸ | HPGD | P15428 | 4/20 | 0.85 |
| ▸ | TP53 | P04637 | 3/20 | 0.85 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.85 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.85 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.85 |
| ▸ | MEN1 | O00255 | 2/20 | 0.85 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.85 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.85 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.85 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.85 |
| ▸ | BCL2 | P10415 | 1/20 | 0.85 |
| ▸ | IL2 | P60568 | 1/20 | 0.85 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.85 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Isoformonentin SCHEMBL30105310 | 1.00 | XDH (1.00) | XDHMAOAMAOBMAPTKDM4E | |
| Formononetin SCHEMBL8416577 | 0.93 | KDM4E (0.97) | XDHMAOAMAOBMAPTKDM4E | |
| Formononetin SCHEMBL62915 | 0.92 | KDM4E (1.00) | XDHMAOAMAOBMAPTKDM4E | |
| Formononetin SCHEMBL29361145 | 0.92 | KDM4E (1.00) | XDHMAOAMAOBMAPTKDM4E | |
| Formononetin SCHEMBL15271536 | 0.92 | KDM4E (1.00) | XDHMAOAMAOBMAPTKDM4E | |
| SCHEMBL571576 | 0.92 | XDH (0.84) | XDHMAOAMAOBMAPTKDM4E | |
| Formononetin SCHEMBL6638953 | 0.91 | KDM4E (0.97) | XDHMAOAMAOBMAPTKDM4E | |
| SCHEMBL5814089 | 0.88 | XDH (0.78) | XDHMAOAMAOBMAPTKDM4E | |
| SCHEMBL32659701 | 0.87 | XDH (0.77) | XDHMAOAMAOBMAPTKDM4E | |
| SCHEMBL13774686 | 0.86 | XDH (0.76) | XDHMAOAMAOBMAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 126 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160068542-A1 | Enhanced Osteogenic Activity of Daidzein Analogs on Human Mesenchymal Stem Cells | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF AGRICULTURE | 2016-03-10 | — | — | US | claimed |
| EP-2981530-A2 | ENHANCED OSTEOGENIC ACTIVITY OF DAIDZEIN ANALOGS ON HUMAN MESENCHYMAL STEM CELLS | The Administrators of the Tulane Educational Fund (US) | 2016-02-10 | — | — | EP | claimed |
| US-20150148409-A1 | NOVEL DAIDZEIN ANALOGS AS TREATMENT FOR CANCER | XAVIER UNIVERSITY OF LOUISIANA | 2015-05-28 | — | — | US | claimed |
| US-8962679-B2 | Daidzein analogs as treatment for cancer | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) | 2015-02-24 | — | — | US | claimed |
| WO-2014165723-A2 | ENHANCED OSTEOGENIC ACTIVITY OF DAIDZEIN ANALOGS ON HUMAN MESENCHYMAL STEM CELLS | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) | 2014-10-09 | — | — | WO | claimed |
| US-20130184475-A1 | NOVEL DAIDZEIN ANALOGS AS TREATMENT FOR CANCER | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) | 2013-07-18 | — | — | US | claimed |
| WO-2012006563-A2 | NOVEL DAIDZEIN ANALOGS AS TREATMENT FOR CANCER | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) | 2012-01-12 | — | — | WO | claimed |
| EP-2278882-A2 | COMPOSITIONS AND METHODS TO CONTROL OOMYCETE FUNGAL PATHOGENS | Dow AgroSciences LLC (US) | 2011-02-02 | — | — | EP | claimed |
| WO-2009146079-A2 | COMPOSITIONS AND METHODS TO CONTROL OOMYCETE FUNGAL PATHOGENS | DOW AGROSCIENCES LLC (US) | 2009-12-03 | — | — | WO | claimed |
| US-20090246293-A1 | COMPOSITIONS AND METHODS TO CONTROL OOMYCETE FUNGAL PATHOGENS | DOW AGROSCIENCES LLC (US) | 2009-10-01 | — | — | US | claimed |
| CN-122097338-A | Application of formononetin in preparation of medicines for preventing and treating depression | — | 2026-05-29 | — | — | CN | disclosed |
| US-12507703-B2 | Methods, devices and compositions for preserving human milk | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2025-12-30 | — | — | US | disclosed |
| US-20250169516-A1 | METHODS, DEVICES AND COMPOSITIONS FOR PRESERVING HUMAN MILK | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2025-05-29 | — | — | US | disclosed |
| US-12239142-B2 | Methods, devices and compositions for preserving human milk | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2025-03-04 | — | — | US | disclosed |
| US-20240268402-A1 | Methods, Devices and Compositions for Preserving Human Milk | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2024-08-15 | — | — | US | disclosed |
| WO-2004002470-A1 | COMPOUNDS USEFUL FOR THE INHIBITION OF ALDH | THE ENDOWMENT FOR RESEARCH IN HUMAN BIOLOGY, INC. (US) | 2004-01-08 | — | — | WO | disclosed |
| WO-2003006987-A9 | METHODS AND COMPOSITIONS FOR DETERMINING ENZYMATIC ACTIVITY AND SPECIFICITY OF METHYLTRANSFERASES | SALK INST FOR BIOLOGICAL STUDI (US) | 2003-04-24 | — | — | WO | disclosed |
| WO-2003006987-A1 | METHODS AND COMPOSITIONS FOR DETERMINING ENZYMATIC ACTIVITY AND SPECIFICITY OF METHYLTRANSFERASES | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2003-01-23 | — | — | WO | disclosed |
| EP-1183376-A1 | ISOFLAVONOID METHYLATION ENZYME | The Samuel Roberts Noble Foundation, Inc. (US) | 2002-03-06 | — | — | EP | disclosed |
| WO-2000071736-A1 | ISOFLAVONOID METHYLATION ENZYME | THE SAMUEL ROBERTS NOBLE FOUNDATION, INC. (US) | 2000-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12507703-B2 | Methods, devices and compositions for preserving human milk | LPL, CEL, LPO | XDH 171/4885MAOA 471/4885MAOB 293/4885 |
| US-20160068542-A1 | Enhanced Osteogenic Activity of Daidzein Analogs on Human Mesenchymal Stem Cells | HPGDS, CXCL12, ALPG | XDH 1126/4885MAOA 2979/4885MAOB 2571/4885 |
| US-20090246293-A1 | COMPOSITIONS AND METHODS TO CONTROL OOMYCETE FUNGAL PATHOGENS | ERG28, DPM1, CYP51A1 | XDH 323/4885MAOA 266/4885MAOB 295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.